"Moderna-Merck mRNA Vaccine Shows Promising Results in Melanoma Trial"

The world's first personalized mRNA cancer vaccine for melanoma, developed by Moderna and Merck, has shown to halve the risk of death or disease recurrence in patients, according to trial results presented at the ASCO annual meeting. The vaccine, used in combination with the immunotherapy Keytruda, demonstrated a 74.8% recurrence-free survival rate over 2.5 years, compared to 55.6% for Keytruda alone. This breakthrough marks a significant advancement in cancer vaccine research, with similar promising results seen in breast cancer trials.